



HOOKIPA RECEIVES ADDITIONAL GRANT SUPPORT FROM FFG FOR DEVELOPMENT OF VACCINE CANDIDATE HB101

VIENNA, AUSTRIA, April 22, 2014 - Hookipa Biotech AG, a biotech company pioneering a new class of vaccines, today announced the award of a major grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public funding agency for translational research in Austria.

A EUR 3.38 million support is given for the second year of a multi-year vaccine development project. The grant will be used to further progress the development of Hookipa's lead product candidate, HB101, a vaccine against cytomegalovirus (CMV) that is currently in advanced pre-clinical testing.

"We have made a very significant progress with our CMV vaccine candidate, and we would like to thank FFG for its continuous support of this important project", commented Dr. Katherine Cohen, CEO of Hookipa Biotech AG.

About Hookipa Biotech AG

Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave[®] technology. The Vaxwave[®] technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The platform is one of the most promising new technologies for next generation vaccines due to its ability to stimulate both potent B-cell and CD8⁺ T-cell immune responses. Vaxwave[®] has been validated in various disease models. Unlike other vectors, Vaxwave[®] vaccines can be administered repeatedly to boost the immune system. The Company is focused on the development of its lead vaccine candidate HB101, a vaccine for immunization against cytomegalovirus (CMV) and plans to further industrialize the Vaxwave[®] technology and build a robust product pipeline in the area of infectious diseases and cancer. Hookipa has raised a total of € 27 million in equity finance from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.



Contact:

Dr. Katherine Cohen
Chief Executive Officer

Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna
Austria
Email: office@hookipabiotech.com